汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688553 汇宇制药

已收盘 07-16 15:00:00

{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":11.93,"timestamp":1721113200000,"preClose":11.95,"halted":0,"volume":760210,"delay":0,"floatShares":291000000,"shares":424000000,"eps":0.349,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"07-16 15:00:00","open":12.01,"high":12.18,"low":11.89,"amount":9109700,"amplitude":0.0243,"askPrice":11.95,"askSize":8,"bidPrice":11.93,"bidSize":11,"shortable":0,"etf":0,"ttmEps":0.349,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721179800000},"adr":0,"adjPreClose":11.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721093400000,1721100600000],[1721106000000,1721113200000]],"highLimit":13.15,"lowLimit":10.75,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"pbRate":1.32,"roa":"--","roe":"1.21%","epsLYR":0.33,"committee":-0.175403,"marketValue":5054000000,"floatMarketCap":3473000000,"peRate":34.18338,"changeRate":-0.0017,"turnoverRate":0.0026,"status":1,"afterMarket":{"amount":0,"volume":0,"close":11.93,"buyVolume":0,"sellVolume":0,"time":1721115239754,"indexStatus":"已收盘 07-16 15:30:00","preClose":11.95}},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2451966349","title":"汇宇制药最新公告：法莫替丁注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2451966349","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451966349?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:31","pubTimestamp":1721122269,"startTime":"0","endTime":"0","summary":"汇宇制药公告，公司全资子公司四川汇宇海玥医药科技有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》，产品名称为法莫替丁注射液。该药品适用于消化性溃疡所致上消化道出血，除肿瘤及食道、胃底静脉曲张以外的各种原因所致的胃及十二指肠粘膜糜烂出血者。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071600035777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2451965736","title":"汇宇制药(688553.SH)：法莫替丁注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2451965736","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451965736?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:27","pubTimestamp":1721122068,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司四川汇宇海玥医药科技有限公司于近日收到国家药品监督管理局核准签发的法莫替丁注射液《药品注册证书》。法莫替丁注射液注册分类为化学药品3类，按照与参比制剂质量和疗效一致的技术要求审评并获批，批准后视同通过仿制药质量和疗效一致性评价。法莫替丁是组胺H2受体的竞争性抑制剂，其通过阻断胃黏膜壁细胞的H2受体，抑制胃酸分泌(包括胃酸浓度和胃液体积)。同时，胃蛋白酶分泌量则与胃液分泌体积成正比。本品适用于消化性溃疡所致上消化道出血，除肿瘤及食道、胃底静脉曲张以外的各种原因所致的胃及十二指肠粘膜糜烂出血者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2451149146","title":"汇宇制药最新公告：注射用HY07121临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451149146","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451149146?lang=zh_cn&edition=full","pubTime":"2024-07-15 18:01","pubTimestamp":1721037671,"startTime":"0","endTime":"0","summary":"汇宇制药公告，公司全资子公司汇宇海玥收到国家药监局核准签发的《受理通知书》，注射用HY07121用于治疗晚期实体瘤的临床试验申请获得受理。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500023888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0239","BK1576","688553","03347","BK1141"],"gpt_icon":0},{"id":"2451261450","title":"汇宇制药(688553.SH)：注射用HY07121获得药物临床试验申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2451261450","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451261450?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:56","pubTimestamp":1721037391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药 发布公告，近日，公司全资子公司四川汇宇海玥医药科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，注射用HY07121用于治疗晚期实体瘤的临床试验申请获得受理。注射用HY07121是公司全资子公司汇宇海玥自主研发的抗PD-1、抗TIGIT、IL-15/IL-15Rα双抗融合蛋白，其注册分类为1类创新型治疗用生物制品。HY07121是一款协同潜力优秀，具备增强肿瘤免疫治疗疗效及克服免疫耐药的一类创新药，预期为晚期肿瘤患者提供新的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0239","688553","BK1583","BK1141","03347"],"gpt_icon":0},{"id":"2451991668","title":"汇宇制药-W7月12日获融资净买入60万元 环比增加447.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451991668","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451991668?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:00","pubTimestamp":1721008813,"startTime":"0","endTime":"0","summary":"7月12日，汇宇制药-W获融资净买入60万元，环比上一交易日增加447.87%。其中，融资买入147万元，融资偿还86万元。A股市场共有1602股获融资净买入，汇宇制药-W净买入额排名第420。股市有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151000479f4bcb8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151000479f4bcb8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2450866062","title":"汇宇制药去年经营遇冷：营收降37.92% 净利跌43.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450866062","media":"铅笔道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450866062?lang=zh_cn&edition=full","pubTime":"2024-07-09 13:33","pubTimestamp":1720503191,"startTime":"0","endTime":"0","summary":"报告期内，汇宇制药实现营业收入9.27亿元，相较上年同期下降37.92%。此外，归属于上市公司股东的净利润为1.40亿元，同比下降43.86%。尽管面临营业收入与净利润的双重下降，汇宇制药在研发方面的投入并未减少。2023年，公司研发费用为3.41亿元，占营业收入的38.48%，较上年增长了14.63个百分点。在业务发展方面，汇宇制药继续深耕国内外市场，特别是在肿瘤治疗领域的药品销售。面对业绩下滑，汇宇制药采取了一系列应对措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407091340239f234071&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407091340239f234071&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553"],"gpt_icon":0},{"id":"2449877463","title":"汇宇制药(688553.SH)：注射用地西他滨获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449877463","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449877463?lang=zh_cn&edition=full","pubTime":"2024-07-08 20:10","pubTimestamp":1720440623,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的注射用地西他滨《药品注册证书》。地西他滨是通过磷酸化后直接掺入DNA，抑制DNA甲基化转移酶，引起DNA低甲基化和细胞分化或凋亡来发挥抗肿瘤作用。注射用地西他滨适用于IPSS评分系统为中危-1、中危-2和高危的初治、复治骨髓增生异常综合征(MDS)患者，包括原发性和继发性的MDS，按照FAB分型所有的亚型：难治性贫血，难治性贫血伴环形铁粒幼细胞增多，难治性贫血伴原始细胞增多，难治性贫血伴原始细胞增多-转化型，慢性粒-单核细胞白血病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2449775728","title":"汇宇制药最新公告：注射用地西他滨获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449775728","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449775728?lang=zh_cn&edition=full","pubTime":"2024-07-08 19:10","pubTimestamp":1720437056,"startTime":"0","endTime":"0","summary":"汇宇制药公告，注射用地西他滨获得药品注册证书。该药品适用于IPSS评分系统为中危-1、中危-2和高危的初治、复治骨髓增生异常综合征（MDS）患者。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800026416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2449062775","title":"汇宇制药：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2449062775","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449062775?lang=zh_cn&edition=full","pubTime":"2024-07-08 19:10","pubTimestamp":1720437032,"startTime":"0","endTime":"0","summary":"每经AI快讯，汇宇制药（SH 688553，收盘价：11.9元）7月8日晚间发布公告称，四川汇宇制药股份有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》。产品名称为“注射用地西他滨”。2023年1至12月份，汇宇制药的营业收入构成为：医药占比99.89%。截至发稿，汇宇制药市值为50亿元。道达号（daoda1997）“个股趋势”提醒：1. 近30日内无机构对汇宇制药-W进行调研。每经头条（nbdtoutiao）——海航濒临“1元”面值退市生死线！方大系，出手了！但部分股民却不满了(记者 王瀚黎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070819105395900665&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070819105395900665&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2449169022","title":"汇宇制药获得实用新型专利授权：“一种瞬转浸染装置及种植系统”","url":"https://stock-news.laohu8.com/highlight/detail?id=2449169022","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449169022?lang=zh_cn&edition=full","pubTime":"2024-07-06 02:59","pubTimestamp":1720205966,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示汇宇制药新获得一项实用新型专利授权，专利名为“一种瞬转浸染装置及种植系统”，专利申请号为CN202323272743.8，授权日为2024年7月5日。今年以来汇宇制药新获得专利授权7个，较去年同期减少了53.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600001897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2448344128","title":"汇宇制药-W申请制药专利，杂质纯度高、检测方法准确度高、降解效率高","url":"https://stock-news.laohu8.com/highlight/detail?id=2448344128","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448344128?lang=zh_cn&edition=full","pubTime":"2024-07-03 12:24","pubTimestamp":1719980654,"startTime":"0","endTime":"0","summary":"金融界2024年7月3日消息，天眼查知识产权信息显示，四川汇宇制药股份有限公司以及四川汇宇海玥医药科技有限公司申请一项名为“一种卡络磺钠降解杂质C及其制备方法、检测方法和用途“，公开号CN202211722628.3，申请日期为2022年12月。专利摘要显示，本发明公开了一种卡络磺钠降解杂质C及其制备方法、检测方法和用途，属于卡络磺钠的药物分析及质量控制领域。本发明提供了一种卡络磺钠降解杂质C及其","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703123723956b5642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703123723956b5642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2448568962","title":"汇宇制药(688553.SH)收到二羟丙茶碱注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448568962","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448568962?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:53","pubTimestamp":1719827591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司全资子公司四川汇宇海玥医药科技有限公司于近日收到国家药品监督管理局核准签发的《药品注册证书》，药品名称为二羟丙茶碱注射液，二羟丙茶碱为平喘药。基本上和氨茶碱相似，其扩张支气管的作用约为氨茶碱的1/10。本品对呼吸道平滑肌有直接松弛作用，能增强膈肌收缩力，改善呼吸功能;还能兴奋心肌，增加心排血量。本品适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状。也可用于因心源性肺水肿而致的喘息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2448913555","title":"汇宇制药撤回阿糖胞苷注射液的注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2448913555","media":"北京商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448913555?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:42","pubTimestamp":1719826930,"startTime":"0","endTime":"0","summary":"7月1日晚间，汇宇制药（688553）发布公告称，公司于近日收到国家药品监督管理局核准签发的《药品注册申请终止通知书》，同意公司撤回阿糖胞苷注射液的注册申请。汇宇制药表示，阿糖胞苷注射液主要适用于成人和儿童急性非淋巴细胞性白血病的诱导缓解和维持治疗。公司于2022年9月向国家药品监督管理局递交该产品的上市注册申请并获得受理。经审慎研究，结合研发策略，公司决定主动撤回本次注册申请。文章来源：北京商报文章作者：丁宁原标题：汇宇制药撤回阿糖胞苷注射液的注册申请","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407012139549eed4475&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407012139549eed4475&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2447655650","title":"汇宇制药公布国际专利申请：“抗体及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2447655650","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447655650?lang=zh_cn&edition=full","pubTime":"2024-06-29 05:36","pubTimestamp":1719610577,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示汇宇制药公布了一项国际专利申请，专利名为“抗体及其用途”，专利申请号为PCT/CN2023/139722，国际公布日为2024年6月27日。专利详情如下：图片来源：世界知识产权组织今年以来汇宇制药已公布的国际专利申请4个，较去年同期增加了300%。结合公司2023年年报财务数据，2023年公司在研发方面投入了3.41亿元，同比减4.33%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062905414895e5eb35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062905414895e5eb35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2446642538","title":"6月27日汇宇制药发布公告，其股东减持1.01万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446642538","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446642538?lang=zh_cn&edition=full","pubTime":"2024-06-27 19:01","pubTimestamp":1719486080,"startTime":"0","endTime":"0","summary":"证券之星消息，6月27日汇宇制药发布公告《汇宇制药:简式权益变动报告书(杨波)》，其股东杨波于2024年6月27日合计减持1.01万股，占公司目前总股本的0.0024%，变动期间该股股价下跌1.9%，截止6月27日收盘报12.41元。股东增减持详情见下表：根据汇宇制药2024年一季报公布的十大股东详情如下：以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700034956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2446580793","title":"汇宇制药：股东杨波通过减持1.01万股，持股比例下降至5.000%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446580793","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446580793?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:51","pubTimestamp":1719485514,"startTime":"0","endTime":"0","summary":"汇宇制药 公告称，股东杨波通过上海证券交易所集中竞价交易的方式减持公司股份数量1.01万股，减持比例0.002%。减持后，杨波持有的汇宇制药股份数量由2119万股减少至2117.99万股，持股比例从5.002%下降至5.000%。此次股权变动不会导致公司控股股东、实际控制人发生变化。该减持计划不触发要约收购，且杨波在本次权益变动后所持有的公司股份均享有表决权，不存在表决权委托或受限等任何权利限制或被限制转让的情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271900149f6bac2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271900149f6bac2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2446581031","title":"汇宇制药(688553.SH)：多西他赛注射液等三项产品获得乌兹别克斯坦上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446581031","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446581031?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:01","pubTimestamp":1719482471,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药 发布公告，公司全资子公司 Seacross Pharmaceuticals Ltd.于近日收到乌兹别克斯坦药品管理局核准签发的关于公司产品多西他赛注射液、奥沙利铂注射液、盐酸伊立替康注射液的上市许可。多西他赛注射液用于局部晚期或转移性乳腺癌、非小细胞肺癌，对头颈部癌、胰腺癌、胃癌、黑色素瘤、软组织肉瘤有一定的疗效。奥沙利铂注射液联合5-氟尿嘧啶和亚叶酸可用于治疗原发肿瘤完全切除后III期结肠癌的辅助治疗，以及转移性结直肠癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2446658149","title":"汇宇制药(688553.SH)股东杨波持股降至5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446658149","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446658149?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:58","pubTimestamp":1719482283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司于2024年6月27日收到股东杨波发来的《关于持股5%以上股东减持至5%权益变动的告知函》及《简式权益变动报告书》。2024年6月27日，股东杨波通过上海证券交易所集中竞价交易的方式减持公司股份10,080股，减持比例0.002%。本次权益变动后，股东杨波持有公司的股份数量从2119万股减少至2117.99万股，持有股份占公司总股本比例从5.002%减少至5%，不再是公司持股5%以上的股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2446270581","title":"汇宇制药最新公告：股东杨波减持至5%以下","url":"https://stock-news.laohu8.com/highlight/detail?id=2446270581","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446270581?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:50","pubTimestamp":1719481806,"startTime":"0","endTime":"0","summary":"汇宇制药公告，股东杨波于2024年6月27日通过上海证券交易所集中竞价交易的方式减持公司股份10,080股，减持比例0.002%。本次权益变动后，杨波持有公司股份从21,190,000股减少至21,179,920股，持有股份占公司总股本比例从5.002%减少至5.000%，不再是公司持股5%以上的股东。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700033955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2446589012","title":"汇宇制药：多西他赛注射液等三项产品获得乌兹别克斯坦上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2446589012","media":"财通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446589012?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:40","pubTimestamp":1719481200,"startTime":"0","endTime":"0","summary":"汇宇制药公告，全资子公司 Seacross Pharmaceuticals Ltd.于近日收到乌兹别克斯坦药品管理局核准签发的关于公司产品多西他赛注射液、奥沙利铂注射液、盐酸伊立替康注射液的上市许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717411095ddc76a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062717411095ddc76a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"None","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688553","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","stockEarnings":[{"period":"1week","weight":0.0232},{"period":"1month","weight":-0.1006},{"period":"3month","weight":-0.0461},{"period":"6month","weight":-0.0815},{"period":"1year","weight":-0.1271},{"period":"ytd","weight":-0.1986}],"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","perCapita":"16587股","boardName":"医药制造业","registeredCapital":"42360万元","compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.031},{"period":"6month","weight":0.0459},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.0005}],"survey":"　　四川汇宇制药股份有限公司主营业务为肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。主要产品有原料药、抗肿瘤注射剂、肿瘤辅助用药、造影剂等。公司荣登“2022年四川省新经济100强企业榜单”；荣获“四川省2022年度科技创新引才引智先进基地”；荣获“2023年中国医药新锐创新力量”；荣获“四川企业技术创新发展能力100强”且名次跃升至第6位；再次斩获“四川企业技术创新发展最具潜力20强企业”；荣获“2023年度科技人才工作先进单位”表彰授牌。","serverTime":1721176376724,"listedPrice":38.87,"stockholders":"17551人(较上一季度减少8.46%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}